In Brief: Pathogenesis TOBI
Executive Summary
Pathogenesis TOBI: Inhaled tobramycin NDA for chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients will be filed in second quarter, company says in announcing Phase III trial results for TOBI. Two trials in 468 patients found that TOBI improved lung function 11% over placebo; mean hospitalization declined 36% to 5.2 days for the TOBI group compared to 8.2 days for placebo...